Biosimilar Contract Manufacturing Market Growth Is Accelerating As Industry Transformation Continues
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Biosimilar Contract Manufacturing Market Revenue Growth Supported By A CAGR Of 20.35% Through 2030
The biosimilar contract manufacturing market has experienced swift expansion in recent years, with its value projected to rise from $9.94 billion in 2025 to $11.49 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.7%. This historical growth has been driven by several factors, including the expiration of patents for reference biologics, the early uptake of biosimilar development initiatives, the broadening of contract manufacturing collaborations, enhanced regulatory frameworks for biosimilars, and a rising incidence of chronic diseases.
The biosimilar contract manufacturing sector is projected to experience significant expansion in the coming years, reaching a valuation of $20.35 billion by 2030, driven by a compound annual growth rate (CAGR) of 15.4%. This anticipated growth during the forecast period stems from several key factors, including a surge in biosimilar approvals worldwide, mounting pressure to lower expenses associated with biologic therapies, an expanding pipeline of biosimilar candidates, heightened investments in large-scale manufacturing infrastructure, and improvements in process optimization techniques. Emerging trends that are expected to shape the market include a growing tendency to contract out biosimilar production, an increased demand for more cost-effective manufacturing approaches, a stronger emphasis on analytical and quality control services, the broadened application of mammalian cell-based production methods, and a heightened focus on meeting regulatory standards.
Download A Free Sample Report For Comprehensive Market Insights:
Biosimilar Contract Manufacturing Market Expansion Supported By Key Demand Factors
The rising incidence of diabetes is anticipated to boost the expansion of the biosimilar contract manufacturing sector. Diabetes prevalence is defined as the percentage of individuals within a population who currently have the condition, indicating a persistent requirement for treatment and long-term therapeutic use. This increase is driven by more sedentary lifestyles and unhealthy eating habits, which contribute to obesity, insulin resistance, and a greater occurrence of type 2 diabetes. Contract manufacturing of biosimilars aids diabetes care by facilitating the affordable, large-scale production of biosimilar insulin and associated biologics. It guarantees steady quality and adherence to regulations, thereby improving patient access to cutting-edge treatments. This enhances the cost-effectiveness of care and broadens worldwide availability of essential diabetes therapies. As an example, in June 2024, data from the National Health Service, a UK government agency, revealed that 3,615,330 patients registered with a general practitioner had non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% rise from 3,065,825 cases in 2022. Consequently, the growing frequency of diabetes is fueling the advancement of the biosimilar contract manufacturing market.
Biosimilar Contract Manufacturing Market Segment Landscape And Growth Potential
The biosimilar contract manufacturing market covered in this report is segmented –
1) By Product Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor, Other Product Types
2) By Service Type: Process Development, Analytical And Quality Control, Fill And Finish Operations, Packaging, Other Service Types
3) By Source: Mammalian, Non-mammalian
4) By Application: Oncology, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
5) By End-Use: Pharmaceutical Companies, Biotech Companies
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Insulin: Rapid Acting Insulin, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Premixed Insulin
3) By Erythropoietin: Alpha Erythropoietin, Beta Erythropoietin, Darbepoetin Alfa, Continuous Erythropoietin Receptor Activators
4) By Granulocyte Colony-Stimulating Factor: Filgrastim, Pegfilgrastim, Lenograstim, Long Acting Granulocyte Colony-Stimulating Factor
5) By Other Product Types: Interferons, Interleukins, Fusion Proteins, Enzyme Therapeutics, Hormonal Biologics
Biosimilar Contract Manufacturing Market Growth Trends Influencing Competitive Dynamics
Key players within the biosimilar contract manufacturing industry are prioritizing the establishment of production facilities, including mirrored single-use plants, to facilitate faster technology transfer, improved scalability, and enhanced commercial reliability. Such mirrored single-use facilities comprise identical production suites utilizing disposable bioprocess equipment and unified digital frameworks, allowing for swift changeovers, consistent quality across different locations, and decreased contamination risks. In September 2025, Rezon Bio, a contract development and manufacturing organization (CDMO) based in Poland, introduced two mirrored-capability single-use biomanufacturing sites covering everything from cell line development to commercial GMP supply. This approach accelerates technology transfer and provides flexible scaling options for biosimilars while cutting downtime, and it bolsters batch-to-batch uniformity through standardized suites, integrated analytics, and logistics automation. Additionally, it reduces total ownership costs for sponsors by limiting cleaning validation requirements, shortening both development and production timelines, and mitigating expansion risks.
Biosimilar Contract Manufacturing Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the biosimilar contract manufacturing market are Thermo Fisher Scientific Inc., Biocon Limited, Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Laboratorios Farmacéuticos Rovi S.A., Vetter Pharma-Fertigung GmbH & Co. KG, National Resilience Inc., Porton Pharma Solutions Co. Ltd., Syngene International Limited, Rentschler Biopharma SE, Boehringer Ingelheim International GmbH, Enzene Biosciences Ltd., Prestige Biologics Co. Ltd., Mabion S.A., HALIX B.V., BioConnection B.V., BioCina Pty Ltd, Mycenax Biotech Inc., Polpharma Biologics S.A.
Access The Complete Biosimilar Contract Manufacturing Market Report:
Biosimilar Contract Manufacturing Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the biosimilar contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
